Designed to Arm the Immune System to Fight Cancer
We are investigating the potential for our lead product candidate, TAVO, through the intratumoral administration of IL-12, to stimulate systemic immune response and to become an innovative and potentially transformative therapy option for the treatment of cancer.
Our core technology platform continues to advance through clinical trials for various cancersLearn More
Our plasmid DNA delivery platform is designed to boost the body’s immune system to target and attack cancerLearn More
We have a track record of establishing, operating and evolving high-performance partnerships globallyLearn More